{
    "nctId": "NCT00103181",
    "briefTitle": "Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer",
    "officialTitle": "A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 4216,
    "primaryOutcomeMeasure": "In-breast tumor recurrence (IBTR)",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed ductal carcinoma in situ (DCIS\\*) or invasive\\* adenocarcinoma of the breast\n\n  * Stage 0, I, or II disease\n\n    * Stage II tumors must be \u2264 3 cm\n  * Gross disease must be unifocal\n\n    * Microscopic multifocality allowed provided total pathological tumor size is \u2264 3 cm\n  * No proven multicentric carcinoma in more than 1 quadrant or separated by \u2265 4 cm\n  * No non-epithelial breast malignancies (e.g., sarcoma or lymphoma) NOTE: \\*Patients who are 50 years of age and over with DCIS regardless of hormone receptor status AND patients with invasive breast cancer meeting all of the following criteria: \u2265 50 years of age, node-negative, and hormone-receptor positive status will not be enrolled in study after 12/30/2006\n* Prior axillary staging required for patients with invasive breast cancer, including 1 of the following:\n\n  * Sentinel node biopsy alone (if sentinel node is negative)\n  * Sentinel node biopsy followed by axillary dissection or sampling with \u2265 6 axillary nodes (if sentinel node is positive)\n  * Axillary dissection alone with \u2265 6 axillary nodes\n* No more than 3 positive axillary nodes\n\n  * No axillary nodes with definite evidence of microscopic or macroscopic extracapsular extension\n  * No positive non-axillary sentinel nodes (intramammary nodes are staged as axillary nodes)\n  * No palpable or radiographically suspicious ipsilateral or contralateral axillary, supraclavicular, infraclavicular, or internal mammary nodes unless there is histologic confirmation that these nodes are negative for tumor\n* Must have undergone lumpectomy\n\n  * Resected margins histologically free of tumor\n  * Re-excision of surgical margins allowed\n  * Target lumpectomy cavity clearly delineated AND target lumpectomy/whole breast reference volume \u2264 30% based on postoperative pre-randomization CT scan\n  * Final surgery (i.e., lumpectomy, re-excision of margins, or axillary staging procedure) within the past 42 days\n* No suspicious microcalcifications, densities, or palpable abnormalities in the ipsilateral or contralateral breast unless biopsied and found to be benign\n* No Paget's disease of the nipple\n* No history of invasive breast cancer or DCIS\n\n  * Prior lobular carcinoma in situ treated by surgery alone allowed\n* No synchronous bilateral invasive or non-invasive breast cancer\n* Partial breast irradiation deemed technically deliverable by radiation oncologist at a credentialed facility\n* Must have undergone a history and physical exam within the past 4 months AND a bilateral mammogram within the past 6 months\n* Hormone receptor status:\n\n  * Estrogen receptor (ER) status known\n  * Progesterone status known if ER analysis is negative\n  * Marginal or borderline results are considered positive\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nSex\n\n* Female\n\nMenopausal status\n\n* Premenopausal or postmenopausal\n\nPerformance status\n\n* Not specified\n\nLife expectancy\n\n* At least 10 years, excluding diagnosis of breast cancer\n\nHematopoietic\n\n* Not specified\n\nHepatic\n\n* Not specified\n\nRenal\n\n* Not specified\n\nOther\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective non-hormonal contraception\n* No other malignancy within the past 5 years except previously treated carcinoma in situ of the cervix or colon, melanoma in situ, or basal cell or squamous cell skin cancer\n\n  * Deemed to be at low risk for recurrence\n* No collagen vascular disease (e.g., systemic lupus erythematosus or scleroderma), specifically dermatomyositis with a creatine phosphokinase (CPK) level above normal, or active skin rash\n* No psychiatric or addictive disorder that would preclude study therapy\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* No prior biologic therapy for this malignancy\n\nChemotherapy\n\n* No prior chemotherapy for this malignancy\n* No concurrent chemotherapy during study radiotherapy\n\nEndocrine therapy\n\n* No prior hormonal therapy for this malignancy unless total duration of hormonal therapy was no more than 28 days before randomization\n* Concurrent hormonal therapy allowed provided it is not administered during chemotherapy\n* No concurrent raloxifene, tamoxifen, or other selective estrogen receptor modulating drugs\n* No concurrent hormone replacement therapy\n* No concurrent Femring\\^\u00ae\n\nRadiotherapy\n\n* No prior radiotherapy for this malignancy\n* No prior breast or thoracic radiotherapy\n* No concurrent brachytherapy boosts\n* No concurrent intensity modulated radiotherapy\n* No concurrent regional nodal irradiation\n\nSurgery\n\n* See Disease Characteristics\n* No prior breast implants\n\n  * Patients who have had implants removed are eligible\n\nOther\n\n* No other concurrent anticancer therapy",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}